This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEH930E0_L.jpg
While scientists are divided over the need for booster shots when so many people in the United States and other countries remain unvaccinated, the Biden administration announced the push for an extra dose in August as part of an effort to shore up protection against the highly transmissible Delta variant.
The U.S. Food and Drug Administration (FDA) last week scheduled an Oct. 15 meeting of its expert advisory committee to discuss whether to grant emergency use authorization for a booster shot of J&J (NYSE:JNJ)’s vaccine.
Over 15 million Americans have received J&J’s vaccine, which is administered as a single dose, according to the latest data https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total from the Centers for Disease Control and Prevention.
The healthcare conglomerate last month said an additional second shot of its vaccine given about two months after the first increased its effectiveness to 94%, compared with 70% protection with the single dose.
J&J declined to comment on the NYT report and pointed to its press release dated Sept. 21, saying the company has submitted available data to the U.S. health regulator and intends to submit the data to other regulators.
The FDA has already authorized a booster dose of the Pfizer Inc (NYSE:PFE) and partner BioNTech vaccine for those 65 and older, people at high risk of severe disease and others who are regularly exposed to the virus.
Rival Moderna (NASDAQ:MRNA) Inc also submitted its application seeking authorization for a booster shot of its two-dose vaccine last month and FDA’s Vaccines and Related Biological Products Advisory Committee panel will hold a meeting on Oct. 14 to discuss the additional dose.
